GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Therapeutics Corp (BSP:U2TH34) » Definitions » Cyclically Adjusted PS Ratio

United Therapeutics (BSP:U2TH34) Cyclically Adjusted PS Ratio : 6.61 (As of Jun. 04, 2025)


View and export this data going back to 2023. Start your Free Trial

What is United Therapeutics Cyclically Adjusted PS Ratio?

As of today (2025-06-04), United Therapeutics's current share price is R$102.50. United Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was R$15.51. United Therapeutics's Cyclically Adjusted PS Ratio for today is 6.61.

The historical rank and industry rank for United Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

BSP:U2TH34' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.88   Med: 5.9   Max: 15.81
Current: 6.98

During the past years, United Therapeutics's highest Cyclically Adjusted PS Ratio was 15.81. The lowest was 2.88. And the median was 5.90.

BSP:U2TH34's Cyclically Adjusted PS Ratio is ranked worse than
86.18% of 738 companies
in the Drug Manufacturers industry
Industry Median: 2.13 vs BSP:U2TH34: 6.98

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

United Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2025 was R$4.706. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is R$15.51 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


United Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for United Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Cyclically Adjusted PS Ratio Chart

United Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.06 6.31 7.27 5.30 7.78

United Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.35 7.26 8.02 7.78 6.61

Competitive Comparison of United Therapeutics's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Cyclically Adjusted PS Ratio falls into.


;
;

United Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

United Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=102.50/15.51
=6.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, United Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=4.706/134.9266*134.9266
=4.706

Current CPI (Mar. 2025) = 134.9266.

United Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 1.041 100.684 1.395
201509 1.501 100.392 2.017
201512 1.581 99.792 2.138
201603 1.401 100.470 1.881
201606 1.506 101.688 1.998
201609 1.437 101.861 1.903
201612 1.514 101.863 2.005
201703 1.262 102.862 1.655
201706 1.632 103.349 2.131
201709 1.582 104.136 2.050
201712 1.740 104.011 2.257
201803 1.454 105.290 1.863
201806 1.931 106.317 2.451
201809 1.927 106.507 2.441
201812 1.683 105.998 2.142
201903 1.593 107.251 2.004
201906 1.637 108.070 2.044
201909 1.880 108.329 2.342
201912 1.458 108.420 1.814
202003 1.974 108.902 2.446
202006 2.115 108.767 2.624
202009 2.301 109.815 2.827
202012 2.190 109.897 2.689
202103 2.302 111.754 2.779
202106 2.373 114.631 2.793
202109 2.466 115.734 2.875
202112 2.451 117.630 2.811
202203 2.409 121.301 2.680
202206 2.450 125.017 2.644
202209 2.778 125.227 2.993
202212 2.609 125.222 2.811
202303 2.662 127.348 2.820
202306 2.924 128.729 3.065
202309 3.028 129.860 3.146
202312 3.012 129.419 3.140
202403 3.395 131.776 3.476
202406 4.053 132.554 4.126
202409 4.284 133.029 4.345
202412 4.629 133.157 4.691
202503 4.706 134.927 4.706

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


United Therapeutics  (BSP:U2TH34) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


United Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


United Therapeutics Business Description

Traded in Other Exchanges
Address
1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

United Therapeutics Headlines

No Headlines